Metagenomi, Inc.

MGX

Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$15.00 6,300,000 Positive High 43.72%

Offering Team

Deal Managers

  • J P Morgan Chase
  • Jefferies
  • Wells Fargo

Lawyers

  • Goodwin Procter LLP

Auditors

  • PricewaterhouseCoopers LLP

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. Genetic mutations are seen in a variety of forms, including deletions, insertions, single-base-pair changes and sequence repeats, and are found throughout the More

Deal Tracker

Investors

Filing

05 Feb, 2024

Offer

09 Feb, 2024

Look Ahead

Lock Up Expiry

09 Aug, 2024

Earning

Nov 1, 2018

IPO Terms

Offer Price $15.00
Offer Size 6M

Market Sentiments

Stock Price